Cytek Biosciences Reports Second Quarter 2026 Financial Results
Summary
Cytek Biosciences reported second-quarter 2026 financial results and raised its full-year revenue outlook slightly. The company posted $48.1 million in revenue, with growth driven by stronger instrument sales in the U.S. and China and continued service expansion. It also launched the Cytek Borealis full spectrum flow cytometer and introduced Aurora Evo configurations with expanded automation. Recurring revenue increased, the installed base reached 3,933 instruments, and management said it will keep investing in products, people, and operations.
Classifications
industries
No industries detected
applications
EduTech - learning
AskAI Classifications
Labels
Biotechnology
Life Sciences
Laboratory Instruments
Linked Companies
Cytek Biosciences
$100M to $250M